A summary of vaccines available at no cost under the National Immunisation Program, incorporating schedule updates effective from mid-2026.
One dose recommended each year, ideally April–May before winter
Replaces Prevenar 13® and Pneumovax 23® — simplified to a single vaccine with broader coverage
Recombinant subunit vaccine — two doses required for full protection
Single dose · Protection lasts at least 2 years · Revaccination timing under review
Annual vaccination based on age and medical risk — primary course recommendations no longer apply
NIP-funded vaccines — patients aged 50 and older · 2026 schedule
| Vaccine | 50–64 (general) | 50–64 (ATSI) | 50+ (medical risk) | 65–74 | 75+ |
|---|---|---|---|---|---|
| Influenza (annual) | ✓ QIP | ✓ | ✓ | ✓ | ✓ |
| Pneumococcal Capvaxive® | — | ✓ (25+) | ✓ | ✓ | ✓ |
| Shingles Shingrix® | — | ✓ (50+) | ⚠ immunocomp. only (18+) |
✓ | ✓ |
| RSV Arexvy® | — | ✓ (60+) | — | — | ✓ |
| COVID-19 | — consider (not funded) |
✓ (50–74) | ✓ severe immunocomp. only |
✓ 1 dose/yr | ✓ 2 doses/yr |